TD 8954

Drug Profile

TD 8954

Alternative Names: TAK 954; TD-8954

Latest Information Update: 10 Jun 2016

Price : $50

At a glance

  • Originator Theravance
  • Developer Theravance; Theravance Biopharma
  • Class Antidementias; Benzimidazoles; Carboxylic acids; Piperidines; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastrointestinal motility disorders
  • Discontinued Alzheimer's disease

Most Recent Events

  • 08 Jun 2016 TD 8954 licensed to Takeda Pharmaceutical worldwide for the treatment of Gastrointestinal motility disorders
  • 12 Apr 2016 Phase-II development is ongoing in Australia
  • 06 Aug 2015 TD 8954 receives Fast Track designation for Gastrointestinal motility disorders [IV,Infusion] (In volunteers) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top